We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(Wiley) Jan 22, 2018 - In a study of patients with head and neck cancer, even mild depressive symptoms were associated with poorer overall survival.
(New York Times) Jan 23, 2018 - A national panel of public health experts concluded in a report released on Tuesday that vaping with e-cigarettes that contain nicotine can be addictive and that teenagers who use the devices may be put at higher risk of switching to traditional smoking.
(USC News) Jan 22, 2018 - A new study from the USC Division of Biokinesiology and Physical Therapy shows how helpful exercise is for female survivors of cancer.
(Forbes) Jan 23, 2018 - TMunity, a biotechnology company founded around the work of cancer immunotherapy pioneer Carl June, says it is raising $100 million from investors including Sean Parker's Parker Institute for Cancer Immunotherapy, drug giant Gilead Sciences, Ping An Ventures, the venture arm of China's largest insurance company, and Be The Match, a patient advocacy group.
(MGH) Jan 22, 2018 - Addition of hydroxyurea to current chemotherapy significantly improved survival in animal models of glioblastoma.
(StreetInsider) Jan 22, 2018 - ChemoCentryx, Inc., announced today positive overall survival (OS) results from an ongoing Phase Ib clinical trial of the Company's second CCR2 inhibitor - CCX872 - in the treatment of locally advanced/metastatic pancreatic cancer.
(PharmaTimes [UK]) Jan 23, 2018 - The European Commission has extended conditional marketing authorisation for Takeda’s Adcetris to include the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) following one prior systemic therapy.
(PharmaTimes [UK]) Jan 23, 2018 - Astellas’ experimental acute myeloid leukaemia drug gilteritinib has been awarded orphan drug designation by the European Commission.
(NCCN) Jan 22, 2018 - A new study in JNCCN finds majority of people with cancer would like their physicians to ask them where they would prefer to receive end-of-life care.
(Yale News) Jan 22, 2018 - As Isoplexis, the company co-founded by Yale’s Rong Fan and Sean Mackay ’14, prepares to take its production to the next level in 2018, two science news publications have honored the company for technology that tailors optimum treatments for cancer patients.